MOLN Key Statistics, Chart & Performance
The current stock price of MOLN is 4.18 USD. In the past month the price decreased by -0.95%. In the past year, price decreased by -17.72%.
MOLN Latest News, Press Relases and Analysis
MOLN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.67 | 395.31B | ||
| AMGN | AMGEN INC | 14.94 | 175.94B | ||
| GILD | GILEAD SCIENCES INC | 14.5 | 147.37B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.21 | 115.43B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.58 | 78.44B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 767 | 51.68B | ||
| INSM | INSMED INC | N/A | 42.80B | ||
| NTRA | NATERA INC | N/A | 31.38B | ||
| BIIB | BIOGEN INC | 10.24 | 25.16B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.95 | 21.53B | ||
| INCY | INCYTE CORP | 15.11 | 19.05B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About MOLN
Company Profile
Molecular Partners AG engages in the provision of development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 153 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Company Info
MOLECULAR PARTNERS AG -ADR
Wagistrasse 14
Schlieren ZUERICH CH
CEO: Patrick Amstutz
Employees: 159
Phone: 41447557700
MOLECULAR PARTNERS AG -ADR / MOLN FAQ
What does MOLECULAR PARTNERS AG -ADR do?
Molecular Partners AG engages in the provision of development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 153 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
What is the stock price of MOLECULAR PARTNERS AG -ADR today?
The current stock price of MOLN is 4.18 USD. The price increased by 2.33% in the last trading session.
What is the dividend status of MOLECULAR PARTNERS AG -ADR?
MOLN does not pay a dividend.
What is the ChartMill technical and fundamental rating of MOLN stock?
MOLN has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists MOLN stock?
MOLN stock is listed on the Nasdaq exchange.
Can you provide the number of employees for MOLECULAR PARTNERS AG -ADR?
MOLECULAR PARTNERS AG -ADR (MOLN) currently has 159 employees.
What is the ownership structure of MOLECULAR PARTNERS AG -ADR (MOLN)?
You can find the ownership structure of MOLECULAR PARTNERS AG -ADR (MOLN) on the Ownership tab.
MOLN Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to MOLN. When comparing the yearly performance of all stocks, MOLN is a bad performer in the overall market: 68.72% of all stocks are doing better.
MOLN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MOLN. The financial health of MOLN is average, but there are quite some concerns on its profitability.
MOLN Financial Highlights
Over the last trailing twelve months MOLN reported a non-GAAP Earnings per Share(EPS) of -1.91. The EPS increased by 16.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -48.19% | ||
| ROE | -56.57% | ||
| Debt/Equity | 0 |
MOLN Forecast & Estimates
9 analysts have analysed MOLN and the average price target is 13.29 USD. This implies a price increase of 218.01% is expected in the next year compared to the current price of 4.18.
For the next year, analysts expect an EPS growth of 9.15% and a revenue growth -75% for MOLN